Phase 2 study of the MEK inhibitor PD-0325901 in patients with advanced non-small cell lung cancer
Latest Information Update: 19 Mar 2009
At a glance
- Drugs Mirdametinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 23 Aug 2007 Status changed from in progress to discontinued.
- 29 Aug 2006 Status change
- 05 Nov 2005 New trial record.